Form 4 for JANX Janux Therapeutics, Inc.

Accepted 2026-01-02 00:00:00 ET · period of report 2026-01-02 · accession 0002005618-26-000002 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-01-02	2026-01-02	JANX	DiRaimondo Thomas	CSO	S - Sale	$13.73	-2,505	124.4K	-2%	-$34.4K
D	2026-01-02	2026-01-02	JANX	DiRaimondo Thomas	CSO	A - Grant	$0.00	+31.4K	155.8K	+25%	$0
D	2026-01-02	2026-01-02	JANX	DiRaimondo Thomas	CSO	A - Grant	$0.00	+109.9K	109.9K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-01-02	S	D	2,505	$13.73	124,425	D	—	—	(F2) Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan. In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024.
2	Common	Common Stock	2026-01-02	A	A	31,400	$0.00	155,825	D	—	—	(F3) Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
3	Derivative	Stock option (right to buy)	2026-01-02	A	A	109,900	$0.00	109,900	D	$13.65 · — to 2036-01-01	109,900 Common Stock	(F4) 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.